MacroGenics reported a quarterly loss of $0.58 per share, slightly wider than the Zacks Consensus Estimate for a $0.57 loss. The result was modestly better than the $0.65 per-share loss posted a year ago, indicating slight year-over-year improvement despite missing expectations by $0.01. The update is routine earnings news for the biotech company and is unlikely to have a large market impact.
MacroGenics reported a quarterly loss of $0.58 per share, slightly wider than the Zacks Consensus Estimate for a $0.57 loss. The result was modestly better than the $0.65 per-share loss posted a year ago, indicating slight year-over-year improvement despite missing expectations by $0.01. The update is routine earnings news for the biotech company and is unlikely to have a large market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
-0.05
Ticker Sentiment
